GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E

被引:33
作者
Ijichi, O
Michel, D
Mertens, T
Miyata, K
Eizuru, Y
机构
[1] Kagoshima Univ, Fac Med, Div Persistent & Oncogen Viruses, Ctr Chron Viral Dis, Kagoshima 8908520, Japan
[2] Kagoshima Univ, Fac Med, Dept Pediat, Kagoshima 8908520, Japan
[3] Univ Ulm, Abt Virol, D-89081 Ulm, Germany
关键词
cytomegalovirus; ganciclovir; phosphorylation UL97; recombinant vaccinia viruses; compensatory mutations;
D O I
10.1016/S0166-3542(01)00202-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A ganciclovir (GCV)-resistant human cytomegalovirus (HCMV) was isolated from an AIDS patient. Molecular analysis of the HCMV UL97 gene revealed two point mutations, A594P and D605E, respectively. In order to evaluate quantitatively the impact of the individual mutations on GCV phosphorylation, recombinant vaccinia viruses (rVVs) were generated carrying either the two mutations (rVV-594/605) or only one mutation (rVV-594 or rVV-605, respectively). In cells infected with the rVV-594/605 double mutant, the GCV phosphorylation was decreased to 50% compared with the phosphorylation in cells infected with the rVV-UL97 wild-type. In cells infected with the rVV-594, however, the GCV phosphorylation was further decreased to 30%. Interestingly, the mutation D605E led to an even better GCV phosphorylation than that measured in cells infected with the rVV-UL97 wild type. These results were confirmed by plaque reduction assays, indicating that rVV-594 was more resistant to GCV than rVV-594/605. In contrast, rVV-605 was more sensitive to GCV than the rVV-UL97 wild type. Therefore, our results demonstrated for the first time that compensatory mutations can also occur in HCMV, as already shown for human immunodeficiency virus type 1. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 33 条
[1]  
AITKHALED M, 1999, ANTIVIR THER S, V4, P52
[2]  
Baldanti F, 1998, ANTIMICROB AGENTS CH, V42, P444
[3]   A 3-NUCLEOTIDE DELETION IN THE UL97 OPEN READING FRAME IS RESPONSIBLE FOR THE GANCICLOVIR RESISTANCE OF A HUMAN CYTOMEGALOVIRUS CLINICAL ISOLATE [J].
BALDANTI, F ;
SILINI, E ;
SARASINI, A ;
TALARICO, CL ;
STANAT, SC ;
BIRON, KK ;
FURIONE, M ;
BONO, F ;
PALU, G ;
GERNA, G .
JOURNAL OF VIROLOGY, 1995, 69 (02) :796-800
[4]  
BALDANTI F, 2002, IN PRESS ANTIVIRAL R, V535
[5]   FREQUENCY OF UL97 PHOSPHOTRANSFERASE MUTATIONS RELATED TO GANCICLOVIR RESISTANCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES [J].
CHOU, SW ;
GUENTZEL, S ;
MICHELS, KR ;
MINER, RC ;
DREW, WL .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (01) :239-242
[6]   ANALYSIS OF THE UL97 PHOSPHOTRANSFERASE CODING SEQUENCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES AND IDENTIFICATION OF MUTATIONS CONFERRING GANCICLOVIR RESISTANCE [J].
CHOU, SW ;
ERICE, A ;
JORDAN, MC ;
VERCELLOTTI, GM ;
MICHELS, KR ;
TALARICO, CL ;
STANAT, SC ;
BIRON, KK .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :576-583
[7]   PREVALENCE OF RESISTANCE IN PATIENTS RECEIVING GANCICLOVIR FOR SERIOUS CYTOMEGALOVIRUS-INFECTION [J].
DREW, WL ;
MINER, RC ;
BUSCH, DF ;
FOLLANSBEE, SE ;
GULLETT, J ;
MEHALKO, SG ;
GORDON, SM ;
OWEN, WF ;
MATTHEWS, TR ;
BUHLES, WC ;
DEARMOND, B .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :716-719
[8]   PROGRESSIVE DISEASE DUE TO GANCICLOVIR-RESISTANT CYTOMEGALO-VIRUS IN IMMUNOCOMPROMISED PATIENTS [J].
ERICE, A ;
CHOU, S ;
BIRON, KK ;
STANAT, SC ;
BALFOUR, HH ;
JORDAN, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) :289-293
[9]   Resistance of human cytomegalovirus to antiviral drugs [J].
Erice, A .
CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (02) :286-+
[10]   Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir [J].
Harada, K ;
Eizuru, Y ;
Isashiki, Y ;
Ihara, S ;
Minamishima, Y .
ARCHIVES OF VIROLOGY, 1997, 142 (02) :215-225